Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.

Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of blood cancers arising in lymphoid tissues that commonly effects both humans and dogs. Protein arginine methyltransferase 5 (PRMT5), an enzyme that catalyzes the symmetric di-methylation of arginine residues, is frequently overexpressed and dysre...

Full description

Bibliographic Details
Main Authors: Shelby L Sloan, Kyle A Renaldo, Mackenzie Long, Ji-Hyun Chung, Lindsay E Courtney, Konstantin Shilo, Youssef Youssef, Sarah Schlotter, Fiona Brown, Brett G Klamer, Xiaoli Zhang, Ayse S Yilmaz, Hatice G Ozer, Victor E Valli, Kris Vaddi, Peggy Scherle, Lapo Alinari, William C Kisseberth, Robert A Baiocchi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0250839

Internet

https://doi.org/10.1371/journal.pone.0250839

Similar Items